HRP20220482T1 - Postupci in vitro diferencijacije neurona dopamina srednjeg mozga (mda) - Google Patents
Postupci in vitro diferencijacije neurona dopamina srednjeg mozga (mda) Download PDFInfo
- Publication number
- HRP20220482T1 HRP20220482T1 HRP20220482TT HRP20220482T HRP20220482T1 HR P20220482 T1 HRP20220482 T1 HR P20220482T1 HR P20220482T T HRP20220482T T HR P20220482TT HR P20220482 T HRP20220482 T HR P20220482T HR P20220482 T1 HRP20220482 T1 HR P20220482T1
- Authority
- HR
- Croatia
- Prior art keywords
- cells
- signaling
- days
- activator
- stem cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 17
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title claims 6
- 229960003638 dopamine Drugs 0.000 title claims 3
- 210000002569 neuron Anatomy 0.000 title claims 3
- 230000004069 differentiation Effects 0.000 title claims 2
- 238000000338 in vitro Methods 0.000 title claims 2
- 210000001259 mesencephalon Anatomy 0.000 title claims 2
- 210000004027 cell Anatomy 0.000 claims 23
- 230000011664 signaling Effects 0.000 claims 19
- 239000012190 activator Substances 0.000 claims 12
- 102000003693 Hedgehog Proteins Human genes 0.000 claims 11
- 108090000031 Hedgehog Proteins Proteins 0.000 claims 11
- 230000004156 Wnt signaling pathway Effects 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 9
- 210000001671 embryonic stem cell Anatomy 0.000 claims 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 4
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 4
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 4
- 108010087745 Hepatocyte Nuclear Factor 3-beta Proteins 0.000 claims 4
- 102100029284 Hepatocyte nuclear factor 3-beta Human genes 0.000 claims 4
- 102100040290 LIM homeobox transcription factor 1-alpha Human genes 0.000 claims 4
- 101710178355 LIM homeobox transcription factor 1-alpha Proteins 0.000 claims 4
- 241000288906 Primates Species 0.000 claims 4
- 241000283984 Rodentia Species 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 3
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 3
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 claims 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims 2
- FHYUGAJXYORMHI-UHFFFAOYSA-N SB 431542 Chemical compound C1=CC(C(=O)N)=CC=C1C1=NC(C=2C=C3OCOC3=CC=2)=C(C=2N=CC=CC=2)N1 FHYUGAJXYORMHI-UHFFFAOYSA-N 0.000 claims 2
- 108091005735 TGF-beta receptors Proteins 0.000 claims 2
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 claims 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 229960005070 ascorbic acid Drugs 0.000 claims 2
- 235000010323 ascorbic acid Nutrition 0.000 claims 2
- 239000011668 ascorbic acid Substances 0.000 claims 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 2
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims 1
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 claims 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 claims 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 claims 1
- 102000013814 Wnt Human genes 0.000 claims 1
- 108050003627 Wnt Proteins 0.000 claims 1
- 102000052547 Wnt-1 Human genes 0.000 claims 1
- 108700020987 Wnt-1 Proteins 0.000 claims 1
- 102000044880 Wnt3A Human genes 0.000 claims 1
- 108700013515 Wnt3A Proteins 0.000 claims 1
- 238000011977 dual antiplatelet therapy Methods 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 108020004017 nuclear receptors Proteins 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- FYBHCRQFSFYWPY-UHFFFAOYSA-N purmorphamine Chemical compound C1CCCCC1N1C2=NC(OC=3C4=CC=CC=C4C=CC=3)=NC(NC=3C=CC(=CC=3)N3CCOCC3)=C2N=C1 FYBHCRQFSFYWPY-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Postupak in vitro diferencijacije pluripotentnih matičnih stanica obuhvaća:
(a) dovođenje u kontakt više pluripotentnih matičnih stanica sa najmanje jednim inhibitorom TGFβ/aktivin-nodalnog signaliziranja; i
(b) dovođenje u kontakt stanica sa najmanje jednim aktivatorom signaliziranja zvučnog ježa (SHH) i najmanje jednim aktivatorom signaliziranja wnt-signalnog puta (Wnt),
pri čemu je koncentracija barem jednog aktivatora signaliziranja Wnt-signalnog puta povećana (i) između 2 dana i 6 dana od njegovog početnog kontakta sa stanicama i (ii) za između 250% i 1800% njegove početne koncentracije dovedene u kontakt sa stanicama, da bi se dobila populacija diferenciranih stanica koje izražavaju forkhead box protein A2 (FOXA2) i LIM homeobox transkripcioni faktor 1 alfa (LMX1A).
2. Postupak iz patentnog zahtjeva 1, još obuhvaća dovođenje u kontakt stanica sa najmanje jednim inhibitorom signaliziranja koštano morfogenetskog proteina (BMP) i Small Mothers Against Decapentaplegic (SMAD) signaliziranja.
3. Postupak iz patentnog zahtjeva 2, pri čemu se stanice dovode u kontakt sa najmanje jednim inhibitorom TGFβ/aktivin-nodalnog signaliziranja, najmanje jednim inhibitorom BMP/SMAD signaliziranja, i najmanje jednim aktivatorom signaliziranja zvučnog ježa (SHH) tokom između 4 dana i 10 dana, ili i do 7 dana, ili tokom najmanje 7 dana.
4. Postupak iz patentnog zahtjeva 2, pri čemu se stanice dovode u kontakt sa najmanje jednim aktivatorom signaliziranja Wnt signalnog puta tokom između 8 i 15 dana, ili tokom ili do 12 dana, ili tokom najmanje 12 dana.
5. Postupak iz bilo kojeg od patentnih zahtjeva 1-4, pri čemu koncentracija najmanje jednog aktivatora signaliziranja Wnt signalnog puta jeste povećana 4 dana od njegovog početnog kontakta sa stanicama.
6. Postupak iz bilo kojeg od patentnih zahtjeva 1-5, pri čemu povećanje koncentracije najmanje jednog aktivatora signaliziranja Wnt signalnog puta je 400% do 1450% od prvobitne koncentracije najmanje jednog aktivatora signaliziranja wnt signalnog puta dovedene u kontakt sa stanicama, ili 700% do 1050% prvobitne koncentracije najmanje jednog aktivatora signaliziranja wnt signalnog puta dovedenog u kontakt s tim stanicama.
7. Postupak iz bilo kojeg od patentnih zahtjeva 1-6, pri čemu povećanje koncentracije najmanje jednog aktivatora signaliziranja Wnt signalnog puta je povećanje do koncentracije od između 3 µM i 10 µM, ili 3 µM, ili 7,5 µM.
8. Postupak iz bilo kojeg od patentnih zahtjeva 1-7, pri čemu te diferencirane stanice izražavaju jednu ili više tirozinskih hidroksilaza (TH), utisnuti engrailed-1 (EN-1), i sa nuklearnim receptorom srodan-1 protein (NURR1), opcionalno pri čemu te diferencirane stanice ne izražavaju detektibilne nivoe familije uparenog boks proteina (PAX6) i/ili Ki67.
9. Postupak iz bilo kojeg od patentnih zahtjeva 1-8, pri čemu taj postupak još obuhvaća izlaganje populacije diferenciranih stanica uvjetima koji pogoduju sazrijevanju stanica u neuronima dopamina, opcionalno pri čemu ti uvjeti obuhvaćaju dovođenje u kontakt stanica sa neurotrofnim moždanim faktorom (BDNF), neurotrofnim glijalnim faktorom (GDNF), cikličnim adenozin monofosfatom (cAMP), transformišućim faktorom rasta beta 3 (TGFβ3), askorbinskom kiselinom (AA), i/ili DAPT.
10. Postupak iz bilo kojeg od patentnih zahtjeva 1-9, pri čemu se te pluripotentne stanice biraju iz grupe koja obuhvaća humane ne-embrione matične stanice, ne-embrione matične stanice primata, ne-embrione matične stanice glodavaca, humane embrione matične stanice, embrione matične stanice primata, embrione matične stanice glodara, pluripotentne matične stanice inducirane iz čovjeka, pluripotentne matične stanice inducirane iz primata, pluripotentne matične stanice inducirane iz glodavca, rekombianantne pluripotentne stanice čovjeka, rekombinantne pluripotentne stanice primata, i rekombinantne pluripotentne stanice glodavca.
11. Postupak iz bilo kojeg od patentnih zahtjeva 2-10, pri čemu
(a) najmanje jedan inhibitor TGFβ/aktivin-nodalnog signaliziranja obuhvaća inhibitor TGFβ receptora, opcionalno pri čemu taj inhibitor TGFβ receptora obuhvaća 4-[4-(1,3-benzodioksol-5-il)-5-(2-piridinil)-1H-imidazol-2-il] benzamid (SB431542); i/ili
(b) najmanje jedan inhibitor BMP i SMAD signaliziranja obuhvaća 4-(6-(4-(piperazin-1- il)fenil)pirazolo[1,5-a]pirimidin-3-il)hinolin (LDN193189), nogin, kombinaciju gore navedenih; i/ili
(c) najmanje jedan aktivator SHH signaliziranja obuhvaća SHH protein, zaglađeni (SMO) agonist, ili kombinaciju gore navedenih, opcionalno (i) pri čemu taj SHH protein obuhvaća rekombinantni SHH, prečišćeni SHH, ili kombinaciju gore navedenih, i/ili (ii) pri čemu taj rekombinantni SHH obuhvaća SHH C25II, i/ili (iii) pri čemu zaglađeni (SMO) agonist obuhvaća purmorfamin; i/ili
(d) najmanje jedan aktivator signaliziranja Wnt signalnog puta obuhvaća CHIR99021, Wnt3A, Wnt1, ili kombinaciju gore navedenih.
12. Postupak iz bilo kojeg od patentnih zahtjeva 1-11, pri čemu su diferencirane stanice koje izražavaju FOXA2 i LMX1A neuroni dopamina srednjeg mozga ili njihovi prekursori.
13. Postupak iz bilo kojeg od patentnih zahtjeva 1-12, pri čemu su pluripotentne matične stanice diferencirane u diferencirane stanice koje izražavaju FOXA2 i LMX1A ne kasnije od između 22 dana i 27 dana od njihovog početnog kontakta sa najmanje jednim inhibitorom TGFβ/aktivin-nodalnog signaliziranja.
14. Postupak iz bilo kojeg od patentnih zahtjeva 1-13, pri čemu te diferencirane stanice izražavaju detektibilni nivo CD142, opcionalno pri čemu taj postupak još obuhvaća odabir populacije stanica koje izražavaju CD142.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562169379P | 2015-06-01 | 2015-06-01 | |
| US201562169444P | 2015-06-01 | 2015-06-01 | |
| PCT/US2016/035312 WO2016196661A1 (en) | 2015-06-01 | 2016-06-01 | Methods of in vitro differentiation of midbrain dopamine (mda) neurons |
| EP16804350.3A EP3303564B1 (en) | 2015-06-01 | 2016-06-01 | Methods of in vitro differentiation of midbrain dopamine (mda) neurons |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220482T1 true HRP20220482T1 (hr) | 2022-07-08 |
Family
ID=57441792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220482TT HRP20220482T1 (hr) | 2015-06-01 | 2016-06-01 | Postupci in vitro diferencijacije neurona dopamina srednjeg mozga (mda) |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10858625B2 (hr) |
| EP (3) | EP4070803A1 (hr) |
| JP (4) | JP6974180B2 (hr) |
| KR (2) | KR102358878B1 (hr) |
| AU (2) | AU2016270793B2 (hr) |
| CA (1) | CA2987617A1 (hr) |
| DK (1) | DK3303564T3 (hr) |
| ES (1) | ES2910032T3 (hr) |
| HR (1) | HRP20220482T1 (hr) |
| HU (1) | HUE058258T2 (hr) |
| IL (2) | IL255992B (hr) |
| LT (1) | LT3303564T (hr) |
| PL (1) | PL3303564T3 (hr) |
| PT (1) | PT3303564T (hr) |
| RS (1) | RS63157B1 (hr) |
| SI (1) | SI3303564T1 (hr) |
| WO (1) | WO2016196661A1 (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019503703A (ja) * | 2016-02-05 | 2019-02-14 | メモリアル スローン ケタリング キャンサー センター | 幹細胞由来外胚葉系統前駆体を分化する方法 |
| CN117467608A (zh) * | 2016-08-16 | 2024-01-30 | 富士胶片细胞动力股份有限公司 | 分化多能细胞的方法 |
| KR20190141218A (ko) * | 2017-04-26 | 2019-12-23 | 메모리얼 슬로안 케터링 캔서 센터 | 사용 준비된 냉동보존 세포 |
| WO2019016113A1 (en) * | 2017-07-17 | 2019-01-24 | Miltenyi Biotec Gmbh | METHOD FOR PROFILING EXPRESSION OF UNICELLULAR PROTEIN FROM DOPAMINERGIC PROGENITOR CELLS OF MESENCEPHALIC FLOOR |
| US20200248139A1 (en) * | 2017-08-08 | 2020-08-06 | Regents Of The University Of Minnesota | Methods for generating and using organoids and cells thereof |
| JP2022534693A (ja) * | 2019-05-23 | 2022-08-03 | ザ マクリーン ホスピタル コーポレーション | パーキンソン病のための自家細胞置換療法 |
| US20220254448A1 (en) | 2019-07-25 | 2022-08-11 | The Scripps Research Institute | Methods of identifying dopaminergic neurons and progenitor cells |
| MX2022002532A (es) * | 2019-08-29 | 2022-06-16 | Memorial Sloan Kettering Cancer Center | Métodos para generar y aislar neuronas de dopamina del mesencéfalo. |
| CA3155277A1 (en) * | 2019-09-20 | 2021-03-25 | Korea Research Institute Of Bioscience And Biotechnology | Production method for induced dopaminergic neuronal progenitors, using direct reprogramming |
| TW202202155A (zh) | 2020-03-25 | 2022-01-16 | 美商薩那生物科技公司 | 用於治療神經病症及病況之低免疫原性神經細胞 |
| WO2021216623A1 (en) | 2020-04-21 | 2021-10-28 | Aspen Neuroscience, Inc. | Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom |
| WO2021216622A1 (en) | 2020-04-21 | 2021-10-28 | Aspen Neuroscience, Inc. | Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom |
| CN116635047A (zh) * | 2020-06-26 | 2023-08-22 | 米纳瓦生物技术公司 | 用于从多能干细胞衍生多巴胺能神经元的方法 |
| WO2021263241A1 (en) * | 2020-06-26 | 2021-12-30 | Minerva Biotechnologies Corporation | Methods for deriving dopaminergic neurons from pluripotent stem cells |
| CA3213988A1 (en) * | 2021-04-07 | 2022-10-13 | Christopher MCMAHON | Dopaminergic precursor cells and methods of use |
| WO2023004370A1 (en) | 2021-07-21 | 2023-01-26 | Aspen Neuroscience, Inc. | Aav-based modulation of gba1 and related compositions and uses thereof |
| US20230081881A1 (en) | 2021-07-21 | 2023-03-16 | Aspen Neuroscience, Inc. | Transposon-based modulation of gba1 and related compositions and uses thereof |
| AU2022387671A1 (en) | 2021-11-12 | 2024-05-16 | Axent Biosciences Inc. | Methods for production of functional neurons |
| WO2023201361A1 (en) | 2022-04-15 | 2023-10-19 | Aspen Neuroscience, Inc. | Methods of classifying the differentiation state of cells and related compositions of differentiated cells |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2395874C (en) | 1999-05-06 | 2011-09-20 | Frank Carter Bancroft | Dna-based steganography |
| JP5943533B2 (ja) | 2000-05-17 | 2016-07-06 | アステリアス バイオセラピューティクス インコーポレイテッド | 神経前駆細胞の集団 |
| US7875273B2 (en) | 2004-12-23 | 2011-01-25 | Ethicon, Incorporated | Treatment of Parkinson's disease and related disorders using postpartum derived cells |
| JP2008511304A (ja) * | 2004-09-02 | 2008-04-17 | ニューロ セラピューティクス エービー | ドーパミンニューロンの増強産生に関する方法と材料 |
| CA2644922C (en) | 2006-03-07 | 2019-07-23 | Geeta Shroff | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation |
| WO2008008266A2 (en) | 2006-07-07 | 2008-01-17 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Biohybrid elastomeric scaffolds and methods of use thereof |
| US8642334B2 (en) | 2009-02-17 | 2014-02-04 | Memorial Sloan Kettering Cancer Center | Methods of neural conversion of human embryonic stem cells |
| CA2800500C (en) | 2010-05-25 | 2019-10-15 | Memorial Sloan-Kettering Cancer Center | Method of nociceptor differentiation of human embryonic stem cells and uses thereof |
| US20110296542A1 (en) | 2010-05-28 | 2011-12-01 | Kevin Ka-Wang Wang | Exogenous matrix-supported topical application of stem cells to organ surface |
| ES2779453T3 (es) | 2011-11-04 | 2020-08-17 | Memorial Sloan Kettering Cancer Center | Neuronas de dopamina (DA) del mesencéfalo para injerto |
| US20150159135A1 (en) | 2012-06-15 | 2015-06-11 | Baylor College Of Medicine | Perineurium Derived Adult Stem Cells and Methods of Use |
| EP2989198A4 (en) | 2013-04-26 | 2016-10-26 | Sloan Kettering Inst Cancer | CORTICAL INTERNEURONES AND OTHER NEURONAL CELLS PRODUCED BY DIRECTED DIFFERENTIATION OF PLURIPOTENT AND MULTIPOTENT CELLS |
| KR101696874B1 (ko) | 2013-07-31 | 2017-01-16 | 한국생명공학연구원 | 직접 리프로그래밍을 통한 유도 도파민성 전구세포 제조방법 |
| AU2014303330B2 (en) | 2013-08-06 | 2020-08-27 | Takeda Pharmaceutical Company Limited | Method for producing dopaminergic neurons |
| WO2015034012A1 (ja) * | 2013-09-05 | 2015-03-12 | 国立大学法人京都大学 | 新規ドーパミン産生神経前駆細胞の誘導方法 |
| CN105940101A (zh) | 2013-11-21 | 2016-09-14 | 纪念斯隆-凯特琳癌症中心 | 由人多能干细胞特化功能性颅基板衍生物 |
| WO2015143342A1 (en) * | 2014-03-21 | 2015-09-24 | Cellular Dynamics International, Inc. | Production of midbrain dopaminergic neurons and methods for the use thereof |
-
2016
- 2016-06-01 DK DK16804350.3T patent/DK3303564T3/da active
- 2016-06-01 KR KR1020177037050A patent/KR102358878B1/ko active IP Right Grant
- 2016-06-01 PT PT168043503T patent/PT3303564T/pt unknown
- 2016-06-01 ES ES16804350T patent/ES2910032T3/es active Active
- 2016-06-01 KR KR1020227003399A patent/KR20220020416A/ko active IP Right Grant
- 2016-06-01 SI SI201631535T patent/SI3303564T1/sl unknown
- 2016-06-01 LT LTEPPCT/US2016/035312T patent/LT3303564T/lt unknown
- 2016-06-01 RS RS20220353A patent/RS63157B1/sr unknown
- 2016-06-01 AU AU2016270793A patent/AU2016270793B2/en active Active
- 2016-06-01 EP EP22157782.8A patent/EP4070803A1/en active Pending
- 2016-06-01 CA CA2987617A patent/CA2987617A1/en active Pending
- 2016-06-01 HR HRP20220482TT patent/HRP20220482T1/hr unknown
- 2016-06-01 JP JP2017562028A patent/JP6974180B2/ja active Active
- 2016-06-01 EP EP16804350.3A patent/EP3303564B1/en active Active
- 2016-06-01 EP EP22176877.3A patent/EP4079314A1/en active Pending
- 2016-06-01 HU HUE16804350A patent/HUE058258T2/hu unknown
- 2016-06-01 WO PCT/US2016/035312 patent/WO2016196661A1/en active Application Filing
- 2016-06-01 PL PL16804350T patent/PL3303564T3/pl unknown
-
2017
- 2017-11-22 US US15/820,941 patent/US10858625B2/en active Active
- 2017-11-29 IL IL255992A patent/IL255992B/en unknown
-
2020
- 2020-06-12 JP JP2020102332A patent/JP2020146060A/ja active Pending
- 2020-11-09 US US17/093,126 patent/US20210123018A1/en active Pending
-
2021
- 2021-12-20 JP JP2021205897A patent/JP2022031961A/ja not_active Withdrawn
-
2022
- 2022-03-20 IL IL291532A patent/IL291532A/en unknown
- 2022-09-09 AU AU2022228216A patent/AU2022228216A1/en active Pending
-
2023
- 2023-11-02 JP JP2023188483A patent/JP2023181494A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016270793B2 (en) | 2022-06-09 |
| AU2016270793A1 (en) | 2017-12-14 |
| JP2020146060A (ja) | 2020-09-17 |
| US20210123018A1 (en) | 2021-04-29 |
| PL3303564T3 (pl) | 2022-05-09 |
| DK3303564T3 (da) | 2022-04-04 |
| ES2910032T3 (es) | 2022-05-11 |
| SI3303564T1 (sl) | 2022-07-29 |
| CA2987617A1 (en) | 2016-12-08 |
| JP2023181494A (ja) | 2023-12-21 |
| AU2022228216A1 (en) | 2022-10-06 |
| IL255992B (en) | 2022-04-01 |
| EP4079314A1 (en) | 2022-10-26 |
| KR20220020416A (ko) | 2022-02-18 |
| JP2022031961A (ja) | 2022-02-22 |
| EP3303564A1 (en) | 2018-04-11 |
| RS63157B1 (sr) | 2022-05-31 |
| EP4070803A1 (en) | 2022-10-12 |
| PT3303564T (pt) | 2022-06-02 |
| IL291532A (en) | 2022-05-01 |
| IL255992A (en) | 2018-01-31 |
| KR20180014743A (ko) | 2018-02-09 |
| US20180094242A1 (en) | 2018-04-05 |
| JP6974180B2 (ja) | 2021-12-01 |
| EP3303564A4 (en) | 2018-10-31 |
| US10858625B2 (en) | 2020-12-08 |
| WO2016196661A1 (en) | 2016-12-08 |
| EP3303564B1 (en) | 2022-02-23 |
| LT3303564T (lt) | 2022-05-10 |
| KR102358878B1 (ko) | 2022-02-08 |
| HUE058258T2 (hu) | 2022-07-28 |
| JP2018522538A (ja) | 2018-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220482T1 (hr) | Postupci in vitro diferencijacije neurona dopamina srednjeg mozga (mda) | |
| JP2018522538A5 (hr) | ||
| Bianchi et al. | Rapid and efficient differentiation of functional motor neurons from human iPSC for neural injury modelling | |
| Hulme et al. | Making neurons, made easy: The use of Neurogenin-2 in neuronal differentiation | |
| Britton et al. | A novel self-organizing embryonic stem cell system reveals signaling logic underlying the patterning of human ectoderm | |
| Koehler et al. | Generation of inner ear sensory epithelia from pluripotent stem cells in 3D culture | |
| Jaeger et al. | Temporally controlled modulation of FGF/ERK signaling directs midbrain dopaminergic neural progenitor fate in mouse and human pluripotent stem cells | |
| CA2920287C (en) | Method for producing dopaminergic neurons | |
| Crompton et al. | Stepwise, non-adherent differentiation of human pluripotent stem cells to generate basal forebrain cholinergic neurons via hedgehog signaling | |
| Zhang | Neural subtype specification from embryonic stem cells | |
| JP2019022511A (ja) | 多分化能細胞および多能性細胞の分化を方向付けることによって発生させる皮質介在ニューロンおよびその他のニューロン細胞 | |
| Dye et al. | How to grow a lung: applying principles of developmental biology to generate lung lineages from human pluripotent stem cells | |
| EP3359649A1 (en) | Means and methods for generating midbrain organoids | |
| Yan et al. | Neural patterning of human induced pluripotent stem cells in 3-D cultures for studying biomolecule-directed differential cellular responses | |
| JP2016518137A5 (hr) | ||
| JP2016537967A5 (hr) | ||
| Vahav et al. | Reconstructed human skin shows epidermal invagination towards integrated neopapillae indicating early hair follicle formation in vitro | |
| JP7463326B2 (ja) | 胃底部組織のインビトロでの製造のための方法及び当該方法と関連した組成物 | |
| JP2019535265A5 (hr) | ||
| Roessler et al. | Differentiation of non-mesencephalic neural stem cells towards dopaminergic neurons | |
| Xu et al. | Retinoic acid promotes neural conversion of mouse embryonic stem cells in adherent monoculture | |
| Rushton et al. | Stimulation of GABA-induced Ca2+ influx enhances maturation of human induced pluripotent stem cell-derived neurons | |
| Zhang et al. | Activation of Wnt signaling increases numbers of enteric neurons derived from neonatal mouse and human progenitor cells | |
| Qin et al. | Direct conversion of human fibroblasts into dopaminergic neuron-like cells using small molecules and protein factors | |
| De la Vega et al. | 3D bioprinting human‐induced pluripotent stem cells and drug‐releasing microspheres to produce responsive neural tissues |